Jie-Wen Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jie-Wen Zhang has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
Shuai Chen
Department of Neurology, Zhengzhou University People's Hospital (Henan Provincial People's Hospital), Zhengzhou 450003, China
16 shared publicationsShuang He
Department of Neurology, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou
14 shared publications- Shuai Chen
Department of Neurology, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, China
10 shared publications Jing-Yu Shao
Department of Neurology, Zhengzhou University People's Hospital (Henan Provincial People's Hospital), Zhengzhou 450003, China
8 shared publicationsHong-Qi Yang
Department of Neurology, Zhengzhou University People's Hospital (Henan Provincial People's Hospital), Zhengzhou 450003, China
6 shared publicationsRong Li
Department of Neurology, Zhengzhou University People's Hospital (Henan Provincial People's Hospital), Zhengzhou 450003, China
6 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 18, 1954812
Preserved olfaction unmasks choroid plexus–related cognitive risk in Parkinson’s disease
Background: Choroid plexus volume (CPV) has been associated with cognitive impairment in Parkinson’s disease (PD), particularly frontal-executive dysfunction, whereas olfactory dysfunction is linked to cognitive deterioration and may reflect greater α-synuclein involvement. Whether olfactory status modifies the association between CPV and cognitive outcomes remains unclear. Methods: We analyzed 718 participants with early-stage PD followed for up to 10 years. Baseline CPV was derived from structural MRI. Hyposmia was defined as an age- and sex-adjusted University of Pennsylvania Smell Identification Test percentile ≤ 15. Kaplan–Meier and multivariable Cox models were used to examine incident cognitive milestone (CogM), including a CPV × olfactory status interaction. CPV was standardized to 1-SD units. Multiple sensitivity analyses assessed robustness. Results: Among 709 participants with olfactory data, 502 (70.8%) had hyposmia. Ten-year CogM-free survival was 59.4%. The primary Cox analysis included 680 participants and 173 CogM events. Among participants with normosmia, each 1-SD increase in CPV was associated with higher CogM risk (HR = 1.63, 95% CI 1.20–2.22, P = 0.002). Hyposmia was associated with higher CogM risk at the mean CPV level (HR = 1.91, 95% CI 1.23–2.97, P = 0.004). The CPV × hyposmia interaction was significant (HR = 0.62, 95% CI 0.43–0.88, P = 0.008); the CPV association was absent in participants with hyposmia (HR = 1.01, 95% CI 0.83–1.22, P = 0.950). Findings were consistent across sensitivity analyses. Conclusion: Olfactory status modified the association between CPV and cognitive outcomes in early PD. Larger CPV was associated with higher CogM risk in participants with preserved olfaction, but not in those with hyposmia. These findings warrant validation in independent cohorts.
- 3 November 2026
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 18, 1954812
Open AccessPreserved olfaction unmasks choroid plexus–related cognitive risk in Parkinson’s disease
Background: Choroid plexus volume (CPV) has been associated with cognitive impairment in Parkinson’s disease (PD), particularly frontal-executive dysfunction, whereas olfactory dysfunction is linked to cognitive deterioration and may reflect greater α-synuclein involvement. Whether olfactory status modifies the association between CPV and cognitive outcomes remains unclear. Methods: We analyzed 718 participants with early-stage PD followed for up to 10 years. Baseline CPV was derived from structural MRI. Hyposmia was defined as an age- and sex-adjusted University of Pennsylvania Smell Identification Test percentile ≤ 15. Kaplan–Meier and multivariable Cox models were used to examine incident cognitive milestone (CogM), including a CPV × olfactory status interaction. CPV was standardized to 1-SD units. Multiple sensitivity analyses assessed robustness. Results: Among 709 participants with olfactory data, 502 (70.8%) had hyposmia. Ten-year CogM-free survival was 59.4%. The primary Cox analysis included 680 participants and 173 CogM events. Among participants with normosmia, each 1-SD increase in CPV was associated with higher CogM risk (HR = 1.63, 95% CI 1.20–2.22, P = 0.002). Hyposmia was associated with higher CogM risk at the mean CPV level (HR = 1.91, 95% CI 1.23–2.97, P = 0.004). The CPV × hyposmia interaction was significant (HR = 0.62, 95% CI 0.43–0.88, P = 0.008); the CPV association was absent in participants with hyposmia (HR = 1.01, 95% CI 0.83–1.22, P = 0.950). Findings were consistent across sensitivity analyses. Conclusion: Olfactory status modified the association between CPV and cognitive outcomes in early PD. Larger CPV was associated with higher CogM risk in participants with preserved olfaction, but not in those with hyposmia. These findings warrant validation in independent cohorts.
- Open Access
- 5 June 2026
- Published by Elsevier in The Journal Of Prevention of Alzheimer's Disease
- Vol. 13 (7) , 100613
Diagnostic performance of an automated plasma p-tau217 chemiluminescent assay for detecting Aβ pathology in a Chinese memory clinic cohort
- 5 June 2026
- Published by Elsevier in The Journal Of Prevention of Alzheimer's Disease
- Vol. 13 (7) , 100613
Open AccessDiagnostic performance of an automated plasma p-tau217 chemiluminescent assay for detecting Aβ pathology in a Chinese memory clinic cohort
- 27 March 2026
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 146, 111683
Serum IGF-1 and anxiety trajectories in Parkinson's disease
- 27 March 2026
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 146, 111683
Serum IGF-1 and anxiety trajectories in Parkinson's disease
- 24 March 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 146, 108294
Striatal DAT and disease progression in Parkinson's disease: New evidence from autonomic dysfunction
- 24 March 2026
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 146, 108294
Striatal DAT and disease progression in Parkinson's disease: New evidence from autonomic dysfunction
- Open Access
- 10 March 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (3) , e71251
Implementing plasma p‐tau217 and cognitive testing for Alzheimer's screening in low‐education populations in central China
INTRODUCTION: We evaluated a pragmatic screening strategy combining brief cognitive assessment with plasma phosphorylated tau217 ( p ‐tau217) in an elderly health screening cohort. METHODS: Participants completed the Memory and Executive Screening (MES) test and plasma biomarker assessment. Cognitive impairment was defined using individualized residual norms derived from an internal reference sample. The p ‐tau217 thresholds were positive predictive value (PPV) ‐oriented and anchored to age‐ and cognitive status‐specific prior probabilities of amyloid‐ β (A β ) pathology. RESULTS: MES‐defined cognitive impairment (≤−2 standard deviation [SD] deviation after adjustment for demographics) was identified in 12.4% of participants. In cognitively unimpaired (CU) individuals, age‐specific thresholds targeting a PPV of 0.7 yielded an overall p ‐tau217 positivity rate of 11.8%, increasing from 3.5% (< 60 years) to 6.3% (60–70 years) and 25.9% (≥70 years). Among cognitively impaired (CI) participants, 26.6% were p ‐tau217 positive. DISCUSSION: This framework supports practical integration of plasma biomarkers into community‐based screening, with longitudinal follow‐up needed to further refine threshold selection. Highlights: Regression‐based residual method reduced education bias, identifying 12.4% with cognitive impairment individuals. Fully automated chemiluminescent assay enabled practical, large‐scale biomarker implementation. Brief screening strategy supports early detection, clinical trial recruitment, and resource allocation in under‐resourced regions.
- 10 March 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (3) , e71251
Open AccessImplementing plasma p‐tau217 and cognitive testing for Alzheimer's screening in low‐education populations in central China
INTRODUCTION: We evaluated a pragmatic screening strategy combining brief cognitive assessment with plasma phosphorylated tau217 ( p ‐tau217) in an elderly health screening cohort. METHODS: Participants completed the Memory and Executive Screening (MES) test and plasma biomarker assessment. Cognitive impairment was defined using individualized residual norms derived from an internal reference sample. The p ‐tau217 thresholds were positive predictive value (PPV) ‐oriented and anchored to age‐ and cognitive status‐specific prior probabilities of amyloid‐ β (A β ) pathology. RESULTS: MES‐defined cognitive impairment (≤−2 standard deviation [SD] deviation after adjustment for demographics) was identified in 12.4% of participants. In cognitively unimpaired (CU) individuals, age‐specific thresholds targeting a PPV of 0.7 yielded an overall p ‐tau217 positivity rate of 11.8%, increasing from 3.5% (< 60 years) to 6.3% (60–70 years) and 25.9% (≥70 years). Among cognitively impaired (CI) participants, 26.6% were p ‐tau217 positive. DISCUSSION: This framework supports practical integration of plasma biomarkers into community‐based screening, with longitudinal follow‐up needed to further refine threshold selection. Highlights: Regression‐based residual method reduced education bias, identifying 12.4% with cognitive impairment individuals. Fully automated chemiluminescent assay enabled practical, large‐scale biomarker implementation. Brief screening strategy supports early detection, clinical trial recruitment, and resource allocation in under‐resourced regions.
- 18 February 2026
- Published by Elsevier in Autonomic Neuroscience
- Vol. 264, 103399
CSF LRRK2: A biomarker for slower autonomic dysfunction progression in sporadic Parkinson's disease
- 18 February 2026
- Published by Elsevier in Autonomic Neuroscience
- Vol. 264, 103399
CSF LRRK2: A biomarker for slower autonomic dysfunction progression in sporadic Parkinson's disease
- 15 July 2025
- Published by Elsevier in Psychoneuroendocrinology
- Vol. 180, 107551
Longitudinal association between plasma epidermal growth factor and the progression of anxiety and depressive symptoms in Parkinson's disease
- 15 July 2025
- Published by Elsevier in Psychoneuroendocrinology
- Vol. 180, 107551
Longitudinal association between plasma epidermal growth factor and the progression of anxiety and depressive symptoms in Parkinson's disease
- Open Access
- 6 May 2025
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 11 (1) , 1-7
Corneal confocal microscopy differentiates patients with secondary parkinsonism from idiopathic Parkinson’s disease
Parkinson’s disease (PD) is characterized by progressive degeneration of dopaminergic neurons in the substantia nigra, while secondary parkinsonism (SP) may be due to drugs, vascular, infectious, inflammatory, or even paraneoplastic etiologies. There is currently no biomarker that accurately distinguishes SP from PD. Corneal confocal microscopy (CCM) identifies corneal nerve loss which is associated with motor, cognitive and autonomic dysfunction in PD patients. This study enrolled participants with PD (n = 45) and SP (n = 25). A subset of patients underwent L-6-18F-fluoro-3,4-dihydroxyphenylalanine (18F-DOPA) positron emission tomography (PET) scan which showed bilateral decreased dopamine uptake in the putamen and caudate of patients with PD, but not in those with SP. Corneal nerve fiber density (CNFD) (P < 0.001) was lower and corneal nerve branch density (CNBD) (P = 0.007) was higher in the PD group compared to the SP group. The receiver operating characteristic (ROC) analysis revealed that combined CNFD and CNBD showed excellent discrimination between SP and PD, with an area under the curve (AUC) of 0.924. CCM may have clinical utility in differentiating patients with SP from PD.
- 6 May 2025
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 11 (1) , 1-7
Open AccessCorneal confocal microscopy differentiates patients with secondary parkinsonism from idiopathic Parkinson’s disease
Parkinson’s disease (PD) is characterized by progressive degeneration of dopaminergic neurons in the substantia nigra, while secondary parkinsonism (SP) may be due to drugs, vascular, infectious, inflammatory, or even paraneoplastic etiologies. There is currently no biomarker that accurately distinguishes SP from PD. Corneal confocal microscopy (CCM) identifies corneal nerve loss which is associated with motor, cognitive and autonomic dysfunction in PD patients. This study enrolled participants with PD (n = 45) and SP (n = 25). A subset of patients underwent L-6-18F-fluoro-3,4-dihydroxyphenylalanine (18F-DOPA) positron emission tomography (PET) scan which showed bilateral decreased dopamine uptake in the putamen and caudate of patients with PD, but not in those with SP. Corneal nerve fiber density (CNFD) (P < 0.001) was lower and corneal nerve branch density (CNBD) (P = 0.007) was higher in the PD group compared to the SP group. The receiver operating characteristic (ROC) analysis revealed that combined CNFD and CNBD showed excellent discrimination between SP and PD, with an area under the curve (AUC) of 0.924. CCM may have clinical utility in differentiating patients with SP from PD.
- 23 March 2025
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 135, 107807
Striatal dopaminergic depletion was associated with motor subtype conversion in Parkinson's disease
- 23 March 2025
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 135, 107807
Striatal dopaminergic depletion was associated with motor subtype conversion in Parkinson's disease
- 8 January 2025
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (6) , 2627-2635
A predictive model for longitudinal cognitive subtypes in Parkinson's disease
Background Longitudinal cognitive changes in Parkinson’s disease (PD) exhibit considerable heterogeneity.Predicting cognitive trajectories in early PD patients can improve prognostic counseling and guide clinical trials. Methods This study included 337 early PD patients with 6-year follow-up in the Parkinson's Progression Markers Initiative (PPMI) database.Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA) to identify subtypes of longitudinal cognitive trajectories, and a nomogram predictive model was constructed using baseline clinical variables. Results The 337 PD patients had a mean age of 61.0 years, mean disease duration of 0.55 years, and mean MoCA score of 27.1 points. Latent class mixed models (LCMM) identified two longitudinal cognitive subtypes: cognitive stable (276 cases, 81.9%) and cognitivel deteriorating (61 cases, 18.1%). The cognitively deteriorating subtype presented poorer baseline cognition, older age, and more severe motor and non-motor symptoms. On biomarkers, the cognitively deteriorating subtype revealed higher serum NFL levels and lower mean striatum DAT uptake. Six baseline clinical variables (age, Letter Number Sequencing score, Symbol Digit Modalities Test score, Benton Judgment of Line Orientation Test score, Hopkins Verbal Learning Test-Revised score, and REM Sleep Behavior Disorder) were selected to construct the nomogram predictive model which achieved an AUC of 0.92.The calibration curve demonstrated high consistency between predicted and observed probabilities.The predictive model has potential utility in disease-modifying clinical trials by pre-screening patients at high risk for cognitive deterioration. Conclusion This study identified two longitudinal cognitive subtypes: cognitive stable and cognitive deterioration within 6-year follow-up, and eighteen percent of early PD patients shared the cognitive deterioration subtype The predictive model, incorporating six baseline variables could estimate the risk of longitudinal cognitive deterioration in PD.
- 8 January 2025
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (6) , 2627-2635
A predictive model for longitudinal cognitive subtypes in Parkinson's disease
Background Longitudinal cognitive changes in Parkinson’s disease (PD) exhibit considerable heterogeneity.Predicting cognitive trajectories in early PD patients can improve prognostic counseling and guide clinical trials. Methods This study included 337 early PD patients with 6-year follow-up in the Parkinson's Progression Markers Initiative (PPMI) database.Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA) to identify subtypes of longitudinal cognitive trajectories, and a nomogram predictive model was constructed using baseline clinical variables. Results The 337 PD patients had a mean age of 61.0 years, mean disease duration of 0.55 years, and mean MoCA score of 27.1 points. Latent class mixed models (LCMM) identified two longitudinal cognitive subtypes: cognitive stable (276 cases, 81.9%) and cognitivel deteriorating (61 cases, 18.1%). The cognitively deteriorating subtype presented poorer baseline cognition, older age, and more severe motor and non-motor symptoms. On biomarkers, the cognitively deteriorating subtype revealed higher serum NFL levels and lower mean striatum DAT uptake. Six baseline clinical variables (age, Letter Number Sequencing score, Symbol Digit Modalities Test score, Benton Judgment of Line Orientation Test score, Hopkins Verbal Learning Test-Revised score, and REM Sleep Behavior Disorder) were selected to construct the nomogram predictive model which achieved an AUC of 0.92.The calibration curve demonstrated high consistency between predicted and observed probabilities.The predictive model has potential utility in disease-modifying clinical trials by pre-screening patients at high risk for cognitive deterioration. Conclusion This study identified two longitudinal cognitive subtypes: cognitive stable and cognitive deterioration within 6-year follow-up, and eighteen percent of early PD patients shared the cognitive deterioration subtype The predictive model, incorporating six baseline variables could estimate the risk of longitudinal cognitive deterioration in PD.